Xolair: FDA Approves Omlyclo as First Biosimilar to Reference Xolair

FDA approves Omlyclo (omalizumab-igec) as the first Xolair (omalizumab) biosimilar in the US, with interchangeability status, offering expanded treatment options for allergic and inflammatory conditions.